Drug intelligence / Profile preview

dolcanatide

Development stage
Phase 2
Lead developer
Salix Pharmaceuticals
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Oral
01

Overview

Dolcanatide is an orally administered, synthetic peptide analog of the human endogenous natriuretic hormone uroguanylin. It acts as a guanylate cyclase C (GC-C) agonist, stimulating GC-C receptors in the gastrointestinal tract to increase cyclic GMP production. This mechanism leads to potential laxative, anti-nociceptive, and anti-inflammatory effects. Dolcanatide was designed with select D-amino acid substitutions for enhanced stability and persistence in the gut lumen compared to natural uroguanylin. It has been investigated primarily for ulcerative colitis, constipation (including opioid-induced constipation), chronic pain associated with gastrointestinal disorders, and colorectal cancer chemoprevention. The drug is minimally absorbed systemically and acts locally within the gut[1][3][4][5][7][8].

Other names
dolcanatide
02

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on dolcanatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dolcanatide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call